IDEAYA initiates Phase 1/2 Part 2 monotherapy expansion for IDE892 in MTAP-deleted cancers
IDYA•Dose escalation and development plans
Dose escalation cleared multiple cohorts; projected efficacious exposures reached with 24-hour EC90 target coverage; maximum tolerated dose not yet reached.
IDE892 is positioned as a combination partner; escalation continues with IDE397 in MTAP NSCLC and PDAC; pan-RAS combination first-patient-in targeted for H2 2026.
The company targets an MTAP/CDKN2A, KRAS, pancreatic cancer R&D Day in Q4 2026; the CDKN2A program targets IND in H1 2027.
IDE892 monotherapy expansion begins in MTAP-deleted cancers
IDEAYA initiated Part 2 monotherapy expansion in its Phase 1/2 study of IDE892 for MTAP-deleted pancreatic cancer and NSCLC.
